Dianthus Therapeutics, Inc. /DE/DNTH
What Dianthus Therapeutics, Inc. /DE/ does.
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (“C1s”) – enabling less frequent and more convenient self-administered subcutaneous (“S.C.”) injections suitable for a pre-filled pen. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. We believe claseprubart has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience.
Our second clinical-stage candidate, DNTH212, is a first and potentially best-in-class, bifunctional fusion protein that targets plasmacytoid dendritic cell (“pDC”) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. DNTH212 is also designed with the potential for patient friendly convenient, infrequent, self-administered S.C. injections suitable for a pre-filled pen.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.8M | $6.2M | $2.0M |
| Net income | -$74.9M | -$71.1M | -$28.5M | -$43.6M | -$85.0M | -$162.3M |
| Free cash flow | -$64.4M | -$60.8M | -$29.4M | -$37.0M | -$78.3M | -$129.3M |
More on DNTH.
- Dianthus Therapeutics, Inc. /DE/ summary
- Dianthus Therapeutics, Inc. /DE/ financial statements
- Dianthus Therapeutics, Inc. /DE/ key metrics
- Dianthus Therapeutics, Inc. /DE/ health scores and style box
- Dianthus Therapeutics, Inc. /DE/ earnings
- Dianthus Therapeutics, Inc. /DE/ dividends
- Dianthus Therapeutics, Inc. /DE/ valuation
- Dianthus Therapeutics, Inc. /DE/ ownership and insiders
- Dianthus Therapeutics, Inc. /DE/ peers
Figures from Dianthus Therapeutics, Inc. /DE/'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.